Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article includes visual documentation of eyebrow morphology during a disease course, but reports no new research findings.

This case report describes a patient with severe alopecia totalis and atopic dermatitis who showed almost complete hair regrowth and improved skin lesions after receiving subcutaneous allergen-specific immunotherapy using house dust mites.

This study found that in Japanese male patients with androgenetic alopecia, dutasteride 0.5 mg daily over 52 weeks was associated with improvements in hair growth and appearance, with reported adverse events mostly mild.

This review discusses the benefits and cardiovascular risks of androgen deprivation therapy for prostate cancer patients, noting that optimizing cardiovascular risk factors is important when using ADT.

This article discusses emerging therapies for androgenetic alopecia, highlighting the use of intradermal dutasteride, but it reports no new clinical findings.

Temporal triangular alopecia is a lifelong condition with hairless patches on the side of the head that may be present from birth.

This report describes six cases of hair loss in African American women after switching to tenofovir alafenamide, suggesting it as a possible adverse effect in this population.

This study found that tenuazonic acid from Alternaria alternata can cause significant damage to vital organs in mice at low doses and highlights the need for regulatory measures to manage its risk in agricultural products.

This study found that oral dutasteride increased hair density but not thickness in female-pattern hair loss patients, suggesting a potential mechanism involving β-catenin activity.

This study found that dutasteride use was associated with a stable decrease in sexual function over four years, with no additional risk based on age or prostate size.

Taking dutasteride every other day works as well as daily and better preserves sexual function.

The authors concluded that intralesional triamcinolone acetonide may benefit patients with patch-type alopecia areata, but the evidence is limited due to small, bias-prone studies with variations in treatment protocols.

This review describes how dutasteride, a dual 5alpha-reductase inhibitor, has improved outcomes in benign prostatic hyperplasia and is being studied for prostate cancer prevention, without new data reported.

The man has Temporal Triangular Alopecia, a stable, non-scarring hair loss condition best treated with hair transplantation.

This study found that type A botulinum toxin treatment significantly increased hair thickness and reduced vellous hair count in patients with androgenetic alopecia, suggesting its potential as an effective therapy.

This study developed and validated a sensitive liquid chromatography–mass spectrometry method to measure aristolochic acid‐I in rat plasma, successfully applying it to pharmacokinetic research.

This study found that treating hair with ATS, formed from fumaric acid and cysteamine, effectively improved hair quality by increasing moisture content and altering the internal structure of strong curls.

This article reviews the use of dermoscopy in distinguishing temporal triangular alopecia from alopecia areata, emphasizing its role in avoiding invasive diagnostics and ineffective treatments; it reports no new clinical findings.

This review paper provides a comprehensive overview of Dutasteride, detailing its pharmacological properties, mechanisms, and therapeutic applications, particularly for androgenetic alopecia and benign prostatic hyperplasia, and discusses its potential use in prostate cancer prevention and transgender medicine.

In this study, injecting two different concentrations of botulinum toxin A was found to be safe and effective for treating androgenetic alopecia in Egyptian men and women, with improvements in hair grade and vellus hair density observed over six months.

In this retrospective study conducted at a trichology clinic, the off-label use of upadacitinib for at least 24 weeks was found to have a promising efficacy and safety profile for treating severe alopecia areata in adolescents.

This study of alopecia areata patients found that a 10 mg twice-daily dose of oral tofacitinib led to significant hair regrowth, suggesting it may be beneficial for treatment.

In this study, Dodatek A operationalizes the Functional Androgen Axis framework by defining three system-level indices and an efficiency metric to describe androgen function, incorporating key methodological improvements and acknowledging significant limitations for future empirical validation.

This study reported that an ATRA-loaded nanostructured lipid carrier gel (ATRA-NLC-Gel) improved symptoms of alopecia areata in mice by enhancing transdermal drug delivery, reducing skin irritation, and promoting hair regrowth through targeted follicle enrichment and pathway activation.

In this study, a novel compound named AH-001 demonstrated effective androgen receptor protein degradation, reducing hair loss progression in a mouse model of androgenetic alopecia, with minimal systemic exposure and side effects, suggesting potential for safer treatment.

Dutasteride may help treat prostate cancer by causing cancer cells to shrink and die.

This article discusses the trichoscopic diagnosis of temporal triangular alopecia, but reports no new clinical results.

Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.

This review found that dutasteride is more effective than finasteride in increasing hair count and shaft thickness for androgenetic alopecia in men, with potential for reduced systemic side effects through mesotherapy, although further research is needed on long-term safety and dosage.